Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 13/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7814990 | 0.89 | P2RX1 (0.74) | MEN1KMT2AP2RX1RXFP1PTGS1 | |
| SCHEMBL13927138 | 0.82 | ALDH1A1 (0.81) | ALDH1A1MEN1KMT2ACYP1A2HTT | |
| SCHEMBL14150061 | 0.81 | RXFP1 (0.64) | ALDH1A1MEN1KMT2AP2RX1RXFP1 | |
| SCHEMBL19002050 | 0.81 | TAS2R14 (0.62) | RXFP1PTGS1GRIK1 | |
| SCHEMBL17925886 | 0.81 | MEN1 (0.57) | ALDH1A1MEN1KMT2ARXFP1CYP1A2 | |
| SCHEMBL16088599 | 0.80 | ALDH1A1 (0.59) | ALDH1A1MEN1KMT2AP2RX1RXFP1 | |
| SCHEMBL16127831 | 0.80 | RXFP1 (0.76) | P2RX1RXFP1PTGS1 | |
| SCHEMBL10797383 | 0.80 | P2RX1 (0.73) | ALDH1A1P2RX1RXFP1PTGS1 | |
| Ammonia Solution, Strong SCHEMBL28873301 | 0.79 | MAPT (0.55) | ALDH1A1MEN1KMT2ARXFP1HTT | |
| SCHEMBL16088608 | 0.78 | CYP1A2 (0.57) | ALDH1A1MEN1KMT2ACYP1A2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9452170-B2 | Compounds and methods for inducing chondrogenesis | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2016-09-27 | — | — | US | disclosed |
| US-20160045514-A1 | COMPOUNDS AND METHODS FOR INDUCING CHONDROGENESIS | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2016-02-18 | — | — | US | disclosed |
| US-20140271955-A1 | COMPOUNDS AND METHODS FOR INDUCING CHONDROGENESIS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160045514-A1 | COMPOUNDS AND METHODS FOR INDUCING CHONDROGENESIS | COL2A1, BMP4, COL1A1 | ALDH1A1 52/4885MEN1 4679/4885KMT2A 3871/4885 |
| US-20140271955-A1 | COMPOUNDS AND METHODS FOR INDUCING CHONDROGENESIS | COL2A1, BMP4, COL1A1 | ALDH1A1 52/4885MEN1 4679/4885KMT2A 3871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.